- Home
- PTGX vs EXG Comparison
PTGX vs EXG Comparison
Compare PTGX & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- EXG
- Stock Information
- Founded
- PTGX 2006
- EXG 2007
- Country
- PTGX United States
- EXG United States
- Employees
- PTGX N/A
- EXG N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- EXG Finance Companies
- Sector
- PTGX Health Care
- EXG Finance
- Exchange
- PTGX Nasdaq
- EXG Nasdaq
- Market Cap
- PTGX 2.7B
- EXG 2.6B
- IPO Year
- PTGX 2016
- EXG N/A
- Fundamental
- Price
- PTGX $37.94
- EXG $8.54
- Analyst Decision
- PTGX Strong Buy
- EXG
- Analyst Count
- PTGX 8
- EXG 0
- Target Price
- PTGX $54.63
- EXG N/A
- AVG Volume (30 Days)
- PTGX 638.0K
- EXG 533.2K
- Earning Date
- PTGX 02-25-2025
- EXG 01-01-0001
- Dividend Yield
- PTGX N/A
- EXG 8.27%
- EPS Growth
- PTGX N/A
- EXG N/A
- EPS
- PTGX 2.68
- EXG N/A
- Revenue
- PTGX $323,795,000.00
- EXG N/A
- Revenue This Year
- PTGX $441.08
- EXG N/A
- Revenue Next Year
- PTGX N/A
- EXG N/A
- P/E Ratio
- PTGX $14.23
- EXG N/A
- Revenue Growth
- PTGX 125.73
- EXG N/A
- 52 Week Low
- PTGX $24.21
- EXG $6.78
- 52 Week High
- PTGX $48.89
- EXG $8.15
- Technical
- Relative Strength Index (RSI)
- PTGX 47.00
- EXG 65.61
- Support Level
- PTGX $35.03
- EXG $8.13
- Resistance Level
- PTGX $38.50
- EXG $8.41
- Average True Range (ATR)
- PTGX 1.55
- EXG 0.09
- MACD
- PTGX 0.15
- EXG 0.04
- Stochastic Oscillator
- PTGX 63.65
- EXG 97.67
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.